Clinical trial NCT02104661 - References

Multiple Sclerosis — Protective Role of Oxcarbazepine in Multiple Sclerosis

Citation(s)

•   Al-Izki S et al
  Selective targeting of neuroprotection to MS lesions: sodium channel blockers in experimental autoimmune encephalomyelitis. In: Multiple Sclerosis Journal.; 2011:S53-S276
•   Al-Izki S, Pryce G, Hankey DJ, Lidster K, von Kutzleben SM, Browne L, Clutterbuck L, Posada C, Edith Chan AW, Amor S, Perkins V, Gerritsen WH, Ummenthum K, Peferoen-Baert R, van der Valk P, Montoya A, Joel SP, Garthwaite J, Giovannoni G, Selwood DL, Baker D
  Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis. Brain. 2014 Jan;137(Pt 1):92-108. doi: 10.1093/brain/awt324. Epub 2013 Nov 27.
•   Altmann DR, Jasperse B, Barkhof F, Beckmann K, Filippi M, Kappos LD, Molyneux P, Polman CH, Pozzilli C, Thompson AJ, Wagner K, Yousry TA, Miller DH
  Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology. 2009 Feb 17;72(7):595-601. doi: 10.1212/01.wnl.0000335765.55346.fc. Epub 2008 Nov 12.
•   Andersohn F, Schade R, Willich SN, Garbe E
  Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology. 2010 Jul 27;75(4):335-40. doi: 10.1212/WNL.0b013e3181ea157e.
•   Barkhof F, Calabresi PA, Miller DH, Reingold SC
  Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol. 2009 May;5(5):256-66. doi: 10.1038/nrneurol.2009.41. Review.
•   Black JA, Liu S, Carrithers M, Carrithers LM, Waxman SG
  Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann Neurol. 2007 Jul;62(1):21-33.
•   Chard DT, Jackson JS, Miller DH, Wheeler-Kingshott CA
  Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes. J Magn Reson Imaging. 2010 Jul;32(1):223-8. doi: 10.1002/jmri.22214.
•   Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, Seaman S, Miller DH, Hale G, Waldmann H, Compston DA
  The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006 Jan;253(1):98-108. Epub 2005 Jul 27.
•   Davis A, Dobson R, Kaninia S, Espasandin M, Berg A, Giovannoni G, Schmierer K
  Change practice now! Using atraumatic needles to prevent post lumbar puncture headache. Eur J Neurol. 2014 Feb;21(2):305-11. doi: 10.1111/ene.12307. Epub 2013 Dec 9.
•   Ebers GC, Heigenhauser L, Daumer M, Lederer C, Noseworthy JH
  Disability as an outcome in MS clinical trials. Neurology. 2008 Aug 26;71(9):624-31. doi: 10.1212/01.wnl.0000313034.46883.16. Epub 2008 May 14.
•   Fisniku LK, Chard DT, Jackson JS, Anderson VM, Altmann DR, Miszkiel KA, Thompson AJ, Miller DH
  Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol. 2008 Sep;64(3):247-54. doi: 10.1002/ana.21423. Erratum in: Ann Neurol. 2009 Feb;65(2):232.
•   Franklin RJ, Ffrench-Constant C
  Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci. 2008 Nov;9(11):839-55. doi: 10.1038/nrn2480. Review.
•   Furby J, Hayton T, Altmann D, Brenner R, Chataway J, Smith KJ, Miller DH, Kapoor R
  A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis. J Neurol. 2010 Sep;257(9):1508-16. doi: 10.1007/s00415-010-5563-y. Epub 2010 May 1.
•   Furby J, Hayton T, Anderson V, Altmann D, Brenner R, Chataway J, Hughes R, Smith K, Miller D, Kapoor R
  Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis. Mult Scler. 2008 Sep;14(8):1068-75. doi: 10.1177/1352458508093617. Epub 2008 Jul 16.
•   Gnanapavan S, Grant D, Morant S, Furby J, Hayton T, Teunissen CE, Leoni V, Marta M, Brenner R, Palace J, Miller DH, Kapoor R, Giovannoni G
  Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression. PLoS One. 2013 Aug 1;8(8):e70019. doi: 10.1371/journal.pone.0070019. Print 2013.
•   Gunnarsson M, Malmeström C, Axelsson M, Sundström P, Dahle C, Vrethem M, Olsson T, Piehl F, Norgren N, Rosengren L, Svenningsson A, Lycke J
  Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol. 2011 Jan;69(1):83-9. doi: 10.1002/ana.22247. Epub 2010 Dec 8.
•   Henderson AP, Trip SA, Schlottmann PG, Altmann DR, Garway-Heath DF, Plant GT, Miller DH
  A preliminary longitudinal study of the retinal nerve fiber layer in progressive multiple sclerosis. J Neurol. 2010 Jul;257(7):1083-91. doi: 10.1007/s00415-010-5467-x. Epub 2010 Feb 9.
•   Henderson AP, Trip SA, Schlottmann PG, Altmann DR, Garway-Heath DF, Plant GT, Miller DH
  An investigation of the retinal nerve fibre layer in progressive multiple sclerosis using optical coherence tomography. Brain. 2008 Jan;131(Pt 1):277-87. Epub 2007 Dec 4.
•   Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A
  The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain. 2001 May;124(Pt 5):962-73.
•   Hobart J
  The Multiple Sclerosis Impact Scale (MSIS-29). In: Quality of Life Measurement in Neurodegenerative and Related Conditions. Cambridge University Press; 2011:pp. 24-40
•   Horsfield MA, Sala S, Neema M, Absinta M, Bakshi A, Sormani MP, Rocca MA, Bakshi R, Filippi M
  Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: application in multiple sclerosis. Neuroimage. 2010 Apr 1;50(2):446-55. doi: 10.1016/j.neuroimage.2009.12.121. Epub 2010 Jan 7.
•   Inglese M, Madelin G, Oesingmann N, Babb JS, Wu W, Stoeckel B, Herbert J, Johnson G
  Brain tissue sodium concentration in multiple sclerosis: a sodium imaging study at 3 tesla. Brain. 2010 Mar;133(Pt 3):847-57. doi: 10.1093/brain/awp334. Epub 2010 Jan 27.
•   Kalkers NF, Barkhof F, Bergers E, van Schijndel R, Polman CH
  The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler. 2002 Dec;8(6):532-3.
•   Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, Chataway J, Hughes RA, Miller DH
  Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol. 2010 Jul;9(7):681-8. doi: 10.1016/S1474-4422(10)70131-9. Epub 2010 Jun 8.
•   Kearney H, Yiannakas MC, Abdel-Aziz K, Wheeler-Kingshott CA, Altmann DR, Ciccarelli O, Miller DH
  Improved MRI quantification of spinal cord atrophy in multiple sclerosis. J Magn Reson Imaging. 2014 Mar;39(3):617-23. doi: 10.1002/jmri.24194. Epub 2013 Apr 30.
•   Koch MW, Polman SK
  Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006453. doi: 10.1002/14651858.CD006453.pub2. Review.
•   Kuhle J, Leppert D, Petzold A, Regeniter A, Schindler C, Mehling M, Anthony DC, Kappos L, Lindberg RL
  Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology. 2011 Apr 5;76(14):1206-13. doi: 10.1212/WNL.0b013e31821432ff. Epub 2011 Feb 23.
•   Kurtzke JF
  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444-52.
•   Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, Edan G
  Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010 Jul;133(Pt 7):1900-13. doi: 10.1093/brain/awq076. Epub 2010 Apr 27.
•   Lidster K et al
  Neuroprotection in a novel optic neuritis model. In: Multiple Sclerosis Journal.; 2011:S227-S505 17
•   Lu CH, Kalmar B, Malaspina A, Greensmith L, Petzold A
  A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament "hook" effect. J Neurosci Methods. 2011 Feb 15;195(2):143-50. doi: 10.1016/j.jneumeth.2010.11.026. Epub 2010 Dec 4.
•   Lycke JN, Karlsson JE, Andersen O, Rosengren LE
  Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):402-4.
•   Malmeström C, Haghighi S, Rosengren L, Andersen O, Lycke J
  Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology. 2003 Dec 23;61(12):1720-5.
•   May TW, Korn-Merker E, Rambeck B
  Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet. 2003;42(12):1023-42. Review.
•   Norgren N, Rosengren L, Stigbrand T
  Elevated neurofilament levels in neurological diseases. Brain Res. 2003 Oct 10;987(1):25-31.
•   Paling D et al
  Total sodium concentration is increased in lesions and normal appearing white matter in Multiple Sclerosis. In: ISMRM.; 2012
•   Petzold A, Altintas A, Andreoni L, Bartos A, Berthele A, Blankenstein MA, Buee L, Castellazzi M, Cepok S, Comabella M, Constantinescu CS, Deisenhammer F, Deniz G, Erten G, Espiño M, Fainardi E, Franciotta D, Freedman MS, Giedraitis V, Gilhus NE, Giovannoni G, Glabinski A, Grieb P, Hartung HP, Hemmer B, Herukka SK, Hintzen R, Ingelsson M, Jackson S, Jacobsen S, Jafari N, Jalosinski M, Jarius S, Kapaki E, Kieseier BC, Koel-Simmelink MJ, Kornhuber J, Kuhle J, Kurzepa J, Lalive PH, Lannfelt L, Lehmensiek V, Lewczuk P, Livrea P, Marnetto F, Martino D, Menge T, Norgren N, Papuc E, Paraskevas GP, Pirttilä T, Rajda C, Rejdak K, Ricny J, Ripova D, Rosengren L, Ruggieri M, Schraen S, Shaw G, Sindic C, Siva A, Stigbrand T, Stonebridge I, Topcular B, Trojano M, Tumani H, Twaalfhoven HA, Vécsei L, Van Pesch V, Vanderstichele H, Vedeler C, Verbeek MM, Villar LM, Weissert R, Wildemann B, Yang C, Yao K, Teunissen CE
  Neurofilament ELISA validation. J Immunol Methods. 2010 Jan 31;352(1-2):23-31. doi: 10.1016/j.jim.2009.09.014. Epub 2009 Oct 24.
•   Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, Giovannoni G
  Quantification of neurodegeneration by measurement of brain-specific proteins. J Neuroimmunol. 2003 May;138(1-2):45-8.
•   Petzold A, de Boer JF, Schippling S, Vermersch P, Kardon R, Green A, Calabresi PA, Polman C
  Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2010 Sep;9(9):921-32. doi: 10.1016/S1474-4422(10)70168-X. Review. Erratum in: Lancet Neurol. 2010 Nov;9(11):1045.
•   Petzold A, Eikelenboom MJ, Keir G, Grant D, Lazeron RH, Polman CH, Uitdehaag BM, Thompson EJ, Giovannoni G
  Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J Neurol Neurosurg Psychiatry. 2005 Feb;76(2):206-11.
•   Petzold A, Rejdak K, Plant GT
  Axonal degeneration and inflammation in acute optic neuritis. J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1178-80.
•   Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ
  The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011 Dec;168(12):1266-77. doi: 10.1176/appi.ajp.2011.10111704.
•   Rocca MA, Horsfield MA, Sala S, Copetti M, Valsasina P, Mesaros S, Martinelli V, Caputo D, Stosic-Opincal T, Drulovic J, Comi G, Filippi M
  A multicenter assessment of cervical cord atrophy among MS clinical phenotypes. Neurology. 2011 Jun 14;76(24):2096-102. doi: 10.1212/WNL.0b013e31821f46b8.
•   Roosendaal SD, Bendfeldt K, Vrenken H, Polman CH, Borgwardt S, Radue EW, Kappos L, Pelletier D, Hauser SL, Matthews PM, Barkhof F, Geurts JJ
  Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler. 2011 Sep;17(9):1098-106. doi: 10.1177/1352458511404916. Epub 2011 May 17.
•   Salzer J, Svenningsson A, Sundström P
  Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler. 2010 Mar;16(3):287-92. doi: 10.1177/1352458509359725. Epub 2010 Jan 19.
•   Schneider T, Wheeler-Kingshott CA, Alexander DC
  In-vivo estimates of axonal characteristics using optimized diffusion MRI protocols for single fibre orientation. Med Image Comput Comput Assist Interv. 2010;13(Pt 1):623-30.
•   Schneider T
  Mapping the axon diameter index in the corpus callosum is clinically feasible. In: ISMRM.; 2012
•   Semra YK, Seidi OA, Sharief MK
  Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol. 2002 Jan;122(1-2):132-9.
•   Solaro C, Restivo D, Mancardi GL, Tanganelli P
  Oxcarbazepine for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study. Neurol Sci. 2007 Jun;28(3):156-8. Epub 2007 Jun 30.
•   Stys PK
  General mechanisms of axonal damage and its prevention. J Neurol Sci. 2005 Jun 15;233(1-2):3-13. Review.
•   Sumowski JF, Wylie GR, Deluca J, Chiaravalloti N
  Intellectual enrichment is linked to cerebral efficiency in multiple sclerosis: functional magnetic resonance imaging evidence for cognitive reserve. Brain. 2010 Feb;133(Pt 2):362-74. doi: 10.1093/brain/awp307. Epub 2009 Dec 14.
•   Teunissen CE, Iacobaeus E, Khademi M, Brundin L, Norgren N, Koel-Simmelink MJ, Schepens M, Bouwman F, Twaalfhoven HA, Blom HJ, Jakobs C, Dijkstra CD
  Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009 Apr 14;72(15):1322-9. doi: 10.1212/WNL.0b013e3181a0fe3f.
•   Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L
  Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998 Jan 29;338(5):278-85.

OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial

Details for clinical trial NCT02104661